Medical Xpress
Bariatric surgery slashes risk of kidney failure, heart attack and death, new data show
Bariatric surgery is proving to be a powerful intervention for patients with obesity and chronic kidney disease, with new research showing dramatic reductions in kidney failure, cardiovascular events, and mortality. The findings, presented at the ASMBS annual meeting, add to growing evidence that weight-loss surgery delivers benefits far beyond the scale. For the millions living with both obesity and CKD, the data make a compelling case for surgery as a frontline treatment strategy.
Read article →New Scientist Health
Man destined to get Alzheimer’s saved by accidental heat therapy
Doug Whitney carries a rare genetic mutation that virtually guarantees early-onset Alzheimer's, yet at an age when the disease should have long taken hold, his mind remains sharp. Researchers believe decades spent working in sweltering engine rooms may have triggered protective biological mechanisms similar to those activated by regular sauna use. The case offers a compelling real-world data point for heat therapy as a potential weapon against one of medicine's most stubborn diseases.
Read article →Medical Xpress
Maternal RSV vaccination and infant nirsevimab immunization found safe and effective
Maternal RSV vaccination and infant nirsevimab immunization have been confirmed as safe and effective whether used independently or in combination, according to new research in Pediatrics. The findings are significant for families navigating overlapping prevention strategies, as both approaches are now widely available. Clinicians can administer these interventions sequentially without compromising safety or efficacy.
Read article →Medical Xpress
Complete remission of aggressive pituitary tumor achieved through immunotherapy
Researchers at the University of Cincinnati Gardner Neuroscience Institute have achieved a world first, putting a rare and aggressive pituitary cancer into complete remission using immunotherapy. The breakthrough marks a significant shift in treatment options for a cancer type that has historically resisted conventional therapies. If the approach holds up in broader trials, it could redefine the standard of care for pituitary tumors worldwide.
Read article →Medical Xpress
FDA grants expanded access to the pancreatic cancer drug daraxonrasib
Patients with metastatic pancreatic ductal adenocarcinoma who have exhausted conventional treatment options now have a path to access daraxonrasib before full approval. The FDA's expanded access designation allows healthcare providers to request the experimental drug on behalf of eligible patients. The move signals growing regulatory confidence in daraxonrasib's potential against one of oncology's most difficult-to-treat cancers.
Read article →Get this delivered every morning
Join thousands of readers who get the world's most important stories, curated daily.
Start reading free →